Merck's Medicaid vaccine demonstration project
Virginia Medicaid has applied for a federal Medicaid waiver to allow it to participate in Merck's vaccine pilot project ("The Pink Sheet" April 13, T&G-3). The waiver would allow the state's Medicaid agency to pay Merck directly for the vaccines, which the company would supply to physician offices. If the waiver is approved, Merck is expected to begin shipments in December, initially focusing on the firm's measles, mumps, rubella vaccine MMRII. Arizona, California, Arkansas and New Jersey have also expressed interest in the pilot project. Payments are based on the discounted price Merck provides to the Centers for Disease Control's vaccines program, plus a fee for distribution. House and Senate legislators reportedly have discussed a change in federal Medicaid statutes to permit states to participate in such a program without going through the waiver process; the issue could come up when Congress reconvenes next year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth